LL-37: The Antimicrobial Peptide Behind the Buzz
A real part of human immunity — and one implicated in autoimmune disease, marketed in ways the evidence doesn't support.
LL-37 is having a marketing moment, which is unfortunate, because the real biology is more interesting — and more double-edged — than the pitch. It is a genuine component of human innate immunity, not an exotic discovery. The problem is the distance between what it does inside the body and what it is being sold to do as an injectable product.
What LL-37 really is
LL-37 is the only human cathelicidin peptide, derived from the precursor protein hCAP18 and produced by neutrophils, monocytes, macrophages, and epithelial cells. As a 2020 review in the journal Vaccines (Pahar, Madonna, Das, Albanesi, Girolomoni — “Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections”) summarizes, it kills bacteria, viruses, and fungi by disrupting their membranes, and it also acts as a signaling molecule bridging innate and adaptive immunity. As basic immunology, it is well established and legitimately important.
That is the foundation the marketing builds on. The construction on top of it is where things go wrong.
LL-37 is a real and important immune peptide — but the same review documents that it can act pathologically, complexing with self-DNA to drive autoimmune inflammation. “Important natural molecule” does not equal “safe to inject more of it.”
Where the claims outrun the data
The marketed promises tend toward broad immune enhancement, treating chronic infections, and general healing. The evidence does not support those leaps.
The gaps that matter
- Human trials are lacking for the supplemental, injected uses being promoted. The same review notes that even experimental approaches — such as an oral Lactococcus lactis construct expressing LL-37 studied for COVID-19 — still require randomized clinical trials before any conclusion. There is no approved injectable LL-37 therapy.
- More is not obviously better. The review describes LL-37 complexed to self-DNA acting as an autoantigen in psoriasis and lupus, triggering interferon production and “uncontrolled inflammation.” Adding more to a tightly regulated system is not self-evidently beneficial and could plausibly be harmful.
- Product quality is a real concern, as with most peptides sold outside approved channels, where purity and dosing are uncertain.
The pattern is a common one: a real molecule with a respectable biological story, repackaged as a treatment for things it has not been tested to treat — while its documented inflammatory downside goes unmentioned.
The takeaway
LL-37 is a legitimate and fascinating piece of human immunity, which is exactly why it makes for persuasive marketing. The honest bottom line is that being an important natural peptide is not the same as being a safe, effective supplement — and the peer-reviewed literature actually flags it as a driver of autoimmune inflammation, not just a defender. Interesting biology, unproven and potentially risky product. Treat the buzz with skepticism.